Due to COVID-19, HCA’s lobby is closed. Learn more about HCA's customer service options during the pandemic.
Cardiac stents were first reviewed by the HTA program in 2009.
- In 2015, the HCA director selected cardiac stents for rereview based on newly available published evidence that could change the original coverage determination.
- In 2016, the HCA director selected cardiac stents for rereview based on newly available published evidence that could change the original coverage determination.
Primary criteria ranking
- Safety = High
- Efficacy = High
- Cost = Medium
- Final key questions
- Draft report: comment and response
- Final evidence report
- Final evidence report: appendices
- Final findings and decision
Assessment timeline (2016)
- Draft key questions published: July 10, 2015
- Public comment period: July 10 to 24, 2015
- Final key questions published: August 31, 2015
- Draft report published: October 20, 2015
- Public comment period: October 20 to November 18, 2015
- Final report published: December 14, 2015
- HTCC public meeting: January 15, 2016
The first aim of this assessment is to systematically review, critically appraise and analyze research evidence comparing the safety and efficacy of percutaneous coronary intervention with stenting (PCI) with medical therapy in patients with stable CAD. If there is evidence that PCI with stenting is more effective than medical therapy alone in preventing death or myocardial infarction (MI) and/or improving patient quality of life, the second aim is to update the 2009 HTA on coronary artery stenting by systematically reviewing, critically appraising and analyzing new research evidence comparing the safety and efficacy of percutaneous coronary intervention with newer generation FDA-approved drug eluting stents (DES) with bare metal stent (BMS).